Genetics of paediatric cardiomyopathies

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Purpose of review Paediatric cardiomyopathy is a rare disease with a genetic basis. The purpose of this review is to discuss the current status of genetic findings in the paediatric cardiomyopathy population and present recent progress in utilizing this information for management and therapy. Recent findings With increased clinical genetic testing, an understanding of the genetic causes of cardiomyopathy is improving and novel causes are identified at a rapid rate. Recent progress in identifying the scope of genetic variation in large population datasets has led to reassessment and refinement of our understanding of the significance of rare genetic variation. As a result, the stringency of variant interpretation has increased, at times leading to revision of previous mutation results. Transcriptome and epigenome studies are elucidating important pathways for disease progression and highlight similarities and differences in pathogenesis from adult cardiomyopathy. Therapy targeted towards the underlying cause of cardiomyopathy is emerging for a number of rare syndromes such as Pompe and Noonan syndromes, and genome editing and induced pluripotent stem cells provide promise for additional precision medicine approaches. Summary Genetics is moving at a rapid pace in paediatric cardiomyopathy. Genetic testing is increasingly being incorporated into clinical care. Although interpretation of rare genetic variation remains challenging, the opportunity to provide management and therapy targeted towards the underlying genetic cause is beginning to be realized.

Original languageEnglish (US)
Pages (from-to)534-540
Number of pages7
JournalCurrent Opinion in Pediatrics
Volume29
Issue number5
DOIs
StatePublished - Oct 1 2017

Fingerprint

Cardiomyopathies
Pediatrics
Genetic Testing
Noonan Syndrome
Induced Pluripotent Stem Cells
Information Management
Precision Medicine
Rare Diseases
Transcriptome
Population
Disease Progression
Therapeutics
Mutation

Keywords

  • genetic variant
  • genome editing
  • induced pluripotent stem cells
  • Noonan syndrome
  • transcriptome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Genetics of paediatric cardiomyopathies. / Ware, Stephanie.

In: Current Opinion in Pediatrics, Vol. 29, No. 5, 01.10.2017, p. 534-540.

Research output: Contribution to journalReview article

@article{9b1053862fa448eaad9419a857eac015,
title = "Genetics of paediatric cardiomyopathies",
abstract = "Purpose of review Paediatric cardiomyopathy is a rare disease with a genetic basis. The purpose of this review is to discuss the current status of genetic findings in the paediatric cardiomyopathy population and present recent progress in utilizing this information for management and therapy. Recent findings With increased clinical genetic testing, an understanding of the genetic causes of cardiomyopathy is improving and novel causes are identified at a rapid rate. Recent progress in identifying the scope of genetic variation in large population datasets has led to reassessment and refinement of our understanding of the significance of rare genetic variation. As a result, the stringency of variant interpretation has increased, at times leading to revision of previous mutation results. Transcriptome and epigenome studies are elucidating important pathways for disease progression and highlight similarities and differences in pathogenesis from adult cardiomyopathy. Therapy targeted towards the underlying cause of cardiomyopathy is emerging for a number of rare syndromes such as Pompe and Noonan syndromes, and genome editing and induced pluripotent stem cells provide promise for additional precision medicine approaches. Summary Genetics is moving at a rapid pace in paediatric cardiomyopathy. Genetic testing is increasingly being incorporated into clinical care. Although interpretation of rare genetic variation remains challenging, the opportunity to provide management and therapy targeted towards the underlying genetic cause is beginning to be realized.",
keywords = "genetic variant, genome editing, induced pluripotent stem cells, Noonan syndrome, transcriptome",
author = "Stephanie Ware",
year = "2017",
month = "10",
day = "1",
doi = "10.1097/MOP.0000000000000533",
language = "English (US)",
volume = "29",
pages = "534--540",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Genetics of paediatric cardiomyopathies

AU - Ware, Stephanie

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Purpose of review Paediatric cardiomyopathy is a rare disease with a genetic basis. The purpose of this review is to discuss the current status of genetic findings in the paediatric cardiomyopathy population and present recent progress in utilizing this information for management and therapy. Recent findings With increased clinical genetic testing, an understanding of the genetic causes of cardiomyopathy is improving and novel causes are identified at a rapid rate. Recent progress in identifying the scope of genetic variation in large population datasets has led to reassessment and refinement of our understanding of the significance of rare genetic variation. As a result, the stringency of variant interpretation has increased, at times leading to revision of previous mutation results. Transcriptome and epigenome studies are elucidating important pathways for disease progression and highlight similarities and differences in pathogenesis from adult cardiomyopathy. Therapy targeted towards the underlying cause of cardiomyopathy is emerging for a number of rare syndromes such as Pompe and Noonan syndromes, and genome editing and induced pluripotent stem cells provide promise for additional precision medicine approaches. Summary Genetics is moving at a rapid pace in paediatric cardiomyopathy. Genetic testing is increasingly being incorporated into clinical care. Although interpretation of rare genetic variation remains challenging, the opportunity to provide management and therapy targeted towards the underlying genetic cause is beginning to be realized.

AB - Purpose of review Paediatric cardiomyopathy is a rare disease with a genetic basis. The purpose of this review is to discuss the current status of genetic findings in the paediatric cardiomyopathy population and present recent progress in utilizing this information for management and therapy. Recent findings With increased clinical genetic testing, an understanding of the genetic causes of cardiomyopathy is improving and novel causes are identified at a rapid rate. Recent progress in identifying the scope of genetic variation in large population datasets has led to reassessment and refinement of our understanding of the significance of rare genetic variation. As a result, the stringency of variant interpretation has increased, at times leading to revision of previous mutation results. Transcriptome and epigenome studies are elucidating important pathways for disease progression and highlight similarities and differences in pathogenesis from adult cardiomyopathy. Therapy targeted towards the underlying cause of cardiomyopathy is emerging for a number of rare syndromes such as Pompe and Noonan syndromes, and genome editing and induced pluripotent stem cells provide promise for additional precision medicine approaches. Summary Genetics is moving at a rapid pace in paediatric cardiomyopathy. Genetic testing is increasingly being incorporated into clinical care. Although interpretation of rare genetic variation remains challenging, the opportunity to provide management and therapy targeted towards the underlying genetic cause is beginning to be realized.

KW - genetic variant

KW - genome editing

KW - induced pluripotent stem cells

KW - Noonan syndrome

KW - transcriptome

UR - http://www.scopus.com/inward/record.url?scp=85023167029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023167029&partnerID=8YFLogxK

U2 - 10.1097/MOP.0000000000000533

DO - 10.1097/MOP.0000000000000533

M3 - Review article

C2 - 28700417

AN - SCOPUS:85023167029

VL - 29

SP - 534

EP - 540

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 5

ER -